TGM4: an immunogenic prostate-restricted antigen

TGM4: an immunogenic prostate-restricted antigen

Background Prostate cancer is the second leading cause of cancer-related death in men in the USA; death occurs when patients progress to metastatic castration-resistant prostate cancer (CRPC). Although immunotherapy with the Food and Drug Administration‐approved vaccine sipuleucel‐T, which targets p...

全面介紹

書目詳細資料
Main Authors: Laura Crowley, Charles G Drake, Ran Reshef, Pawel Muranski, Aleksandar Obradovic, Timothy O’Donnell, Uri Laserson, Tiezheng Yuan, Emmanuel S Antonarakis, Zoila A Lopez-Bujanda, Thomas R Nirschl, Rodney Macedo, Alexandros Papachristodoulou, Jelani C Zarif, Mithil K Soni, Michael C Haffner, H Benjamin Larman, Michael M Shen
格式: Article
語言:English
出版: BMJ Publishing Group 2021-06-01
叢編:Journal for ImmunoTherapy of Cancer
在線閱讀:https://jitc.bmj.com/content/9/6/e001649.full

因特網

https://jitc.bmj.com/content/9/6/e001649.full

相似書籍